Lv6
2250 积分 2022-11-29 加入
Maintenance olaparib monotherapy in patients with platinum-sensitive relapsed ovarian cancer without a germline BRCA1 and/or BRCA2 mutation: Final overall survival results from the OPINION trial
1天前
待确认
Real-world applications of PARPi maintenance therapy for recurrent ovarian cancer: A single-center study in China
1天前
求助中
Neoadjuvant treatment with disitamab vedotin plus perioperative toripalimab in patients with HER2-expressing muscle-invasive bladder cancer (MIBC) in the phase II RC48-C017 trial: Updated results
1个月前
已关闭
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer
1个月前
已完结
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer
1个月前
已完结
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
1个月前
已完结
Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer
1个月前
已完结
TROP2 expression as prognostic marker for gastric carcinoma
2个月前
已完结
妇科恶性肿瘤抗体偶联药物临床应用指南（2024年版）
2个月前
已完结
Datopotamab deruxtecan, a novel TROP2-tareting antibody-drug conjugate with a topoisomerase I inhibitor payload, shows preclinical activity against primary and metastatic uterine and ovarian TROP2 over-expressing carcinosarcoma
2个月前
已完结
皖公网安备34019202002308
